All In Biotech

Drug Trial Radar · NCT00845728

Exacerbation Study

A Phase IIIb Multicenter, 52 Week Treatment, Randomized, Blinded, Double Dummy, Parallel Group Efficacy Study Comparing the Effect of Inhaled Indacaterol 150 µg o.d. vs Inhaled Tiotropium 18 µg o.d. on Lung Function, Rate of Exacerbations and Related Outcomes in Patients With COPD

Last checked: Nov 20, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,439 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,439

Actual

Start

Mar 2009

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares indacaterol with tiotropium in terms of bronchodilation over 52 weeks

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Indacaterol 150 µgDrug

    Indacaterol 150 µg o.d. delivered via SDDPI

  • TiotropiumDrug

    Tiotropium 18 µg o.d. delivered via handihaler®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough Forced Expiratory Volume in 1 Second (FEV1).Time frame: 12 weeks

Locations

423 sites in 40 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Capital Federal, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Pilar, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mendoza, Mendoza Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Novartis Investigative Site

    Tauranga, New Zealand, Australia

  • Novartis Investigative Site

    Bankstown, New South Wales, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Daw Park, South Australia, Australia

  • Novartis Investigative Site

    Heidelberg, Victoria, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Nedlands, Western Australia, Australia

  • Novartis Investigative Site

    Feldbach, Austria, Austria

  • Novartis Investigative Site

    Gänserndorf, Austria, Austria

  • Novartis Investigative Site

    Grieskirchen, Austria, Austria

  • Novartis Investigative Site

    Hallein, Austria, Austria

  • Novartis Investigative Site

    Linz, Austria, Austria

  • Novartis Investigative Site

    Perg, Austria, Austria

  • Novartis Investigative Site

    Zwettl Stadt, Austria, Austria

  • Novartis Investigative Site

    Aalst, Belgium

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Duffel, Belgium

  • Novartis Investigative Site

    Eupen, Belgium

  • Novartis Investigative Site

    Godinne, Belgium

  • Novartis Investigative Site

    Gozée, Belgium

  • Novartis Investigative Site

    Herentals, Belgium

  • Novartis Investigative Site

    Jambes, Belgium

  • Novartis Investigative Site

    Jette, Belgium

  • Novartis Investigative Site

    Kortrijk, Belgium

Showing 40 of 423 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.